These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
550 related articles for article (PubMed ID: 36330457)
1. Identification and Validation of a Novel Necroptosis-Related Long Noncoding RNA Prognostic Signature for Lung Adenocarcinoma. Zeng C; Yu H; Liu X; Liu Q; Jin J Biomed Res Int; 2022; 2022():9710540. PubMed ID: 36330457 [TBL] [Abstract][Full Text] [Related]
2. The necroptosis-related signature and tumor microenvironment immune characteristics associated with clinical prognosis and drug sensitivity analysis in stomach adenocarcinoma. Yang B; Wang Y; Liu T; Zhang M; Luo T Aging (Albany NY); 2024 Mar; 16(7):6098-6117. PubMed ID: 38546403 [TBL] [Abstract][Full Text] [Related]
3. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs. Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H Front Immunol; 2022; 13():916800. PubMed ID: 35860239 [TBL] [Abstract][Full Text] [Related]
4. A Novel Necroptosis-Related lncRNA Signature Predicts the Prognosis of Lung Adenocarcinoma. Lu Y; Luo X; Wang Q; Chen J; Zhang X; Li Y; Chen Y; Li X; Han S Front Genet; 2022; 13():862741. PubMed ID: 35368663 [No Abstract] [Full Text] [Related]
5. Identification and validation of tryptophan metabolism-related lncRNAs in lung adenocarcinoma prognosis and immune response. Gao M; Wang M; Chen Y; Wu J; Zhou S; He W; Shu Y; Wang X J Cancer Res Clin Oncol; 2024 Apr; 150(4):171. PubMed ID: 38558328 [TBL] [Abstract][Full Text] [Related]
6. Identification and validation of a novel prognostic model of inflammation-related gene signature of lung adenocarcinoma. Luo D; Feng W; Ma Y; Jiang Z Sci Rep; 2022 Aug; 12(1):14729. PubMed ID: 36042374 [TBL] [Abstract][Full Text] [Related]
7. Cross-talk between necroptosis-related lncRNAs to construct a novel signature and predict the immune landscape of lung adenocarcinoma patients. Wu J; Song D; Zhao G; Chen S; Ren H; Zhang B Front Genet; 2022; 13():966896. PubMed ID: 36186456 [No Abstract] [Full Text] [Related]
8. Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD. Ma C; Gu Z; Yang Y J Cell Mol Med; 2024 Apr; 28(8):e18282. PubMed ID: 38647237 [TBL] [Abstract][Full Text] [Related]
9. Immunogenic cell death-related long noncoding RNA influences immunotherapy against lung adenocarcinoma. Sun D; Zhang C Oncol Res; 2023; 31(5):753-767. PubMed ID: 37547766 [TBL] [Abstract][Full Text] [Related]
10. Disulfidptosis-related lncRNAs signature predicting prognosis and immunotherapy effect in lung adenocarcinoma. Hong S; Zhang Y; Wang D; Wang H; Zhang H; Jiang J; Chen L Aging (Albany NY); 2024 Jun; 16(11):9972-9989. PubMed ID: 38862217 [TBL] [Abstract][Full Text] [Related]
11. Construction of a novel necroptosis-related lncRNA signature for prognosis prediction in esophageal cancer. Liu Y; Hao H; Kang L; Zheng G; Guo X; Li B; Zhao H; Hao H BMC Gastroenterol; 2022 Jul; 22(1):345. PubMed ID: 35840890 [TBL] [Abstract][Full Text] [Related]
12. A methylation-related lncRNA-based prediction model in lung adenocarcinomas. Yang K; Liu H; Li JH Clin Respir J; 2024 Aug; 18(8):e13753. PubMed ID: 39187946 [TBL] [Abstract][Full Text] [Related]
13. Construction of an immune-related lncRNA signature pair for predicting oncologic outcomes and the sensitivity of immunosuppressor in treatment of lung adenocarcinoma. Zhuang J; Chen Z; Chen Z; Chen J; Liu M; Xu X; Liu Y; Yang S; Hu Z; He F Respir Res; 2022 May; 23(1):123. PubMed ID: 35562727 [TBL] [Abstract][Full Text] [Related]
14. A novel necroptosis-related long noncoding RNA model for predicting clinical features, immune characteristics, and therapeutic response in clear cell renal cell carcinoma. Zhang L; Chen Y; Hu W; Wu B; Ye L; Wang D; Bai T Front Immunol; 2023; 14():1230267. PubMed ID: 37600792 [TBL] [Abstract][Full Text] [Related]
15. Establishment of a novel signature to predict prognosis and immune characteristics of pancreatic cancer based on necroptosis-related long non-coding RNA. Xiong Y; Kong X; Fang K; Sun G; Tu S; Wei Y; Ouyang Y; Wan R; Xiao W Mol Biol Rep; 2023 Sep; 50(9):7405-7419. PubMed ID: 37452900 [TBL] [Abstract][Full Text] [Related]
16. Risk coefficient model of necroptosis-related lncRNA in predicting the prognosis of patients with lung adenocarcinoma. Chen H; Xie Z; Li Q; Qu G; Tan N; Zhang Y Sci Rep; 2022 Jun; 12(1):11005. PubMed ID: 35768485 [TBL] [Abstract][Full Text] [Related]
17. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma. Wang F; Lin H; Su Q; Li C World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740 [TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature. Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988 [TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma. Chen JH; Wu X; Wang ZM; Liu ZY; He BX; Song WP; Zhang WZ J Thorac Dis; 2023 Mar; 15(3):1373-1386. PubMed ID: 37065578 [TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and Prognostic Value of Necroptosis-Associated lncRNA Model in Patients with Kidney Renal Clear Cell Carcinoma. Gu J; He Z; Huang Y; Luan T; Chen Z; Wang J; Ding M Dis Markers; 2022; 2022():5204831. PubMed ID: 35664432 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]